Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/6/2008

833)

Additions to marketable securities

and long-term investments (3,733) (4,230)

Proceeds from sale of marketable

securities and investments 3,878 2,548

Other investing activities, net - (337)

Net cash used in investing activities (29,359) (37,852)

Cash Flows from Financing Activities:

Payments on term loan, current debt

and other long-term liabilities (95,000) (251,881)

Proceeds from issuance of short-term debt 17,003 -

Proceeds from stock plans 2,194 11,172

Other (109) -

Net cash used in financing activities (75,912) (240,709)

Net decrease in cash and cash equivalents 60,915 (79,319)

Cash and cash equivalents at beginning of

period 204,554 154,171

Cash and cash equivalents at end of period $265,469 $74,852

The following table presents a reconciliation of reported net income and diluted earnings per share to adjusted net income and diluted earnings per share for the three and six months ended June 30, 2008 and 2007:

Table 4

Watson Pharmaceuticals, Inc.

Reconciliation Table

(Unaudited; in thousands except per share amounts)

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

GAAP to adjusted net income

calculation

Reported GAAP net income $60,303
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Watson Receives FDA Approval for Generic Accuneb(R)
3. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
4. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
6. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
7. Watson Files FDA Application for Generic LYBREL(R)
8. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
9. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Ascendis Pharma A/S ... applies its innovative TransCon technology to address significant ... from a six-month Phase 2 study to evaluate ... Hormone in 53 treatment-naïve, pre-pubertal children with growth ... extremely pleased with the top-line results from our ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... -- Sanofi, un leader mondial et ... le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription :  ... sommaire de l,interview :  - Résultats ... - Diabète - Praluent ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... , ... new market research report is available in its catalogue: ... , http://www.reportlinker.com/p0164232/Neurostimulation---A-Global-Market-Perspective.html , The world neurostimulation ... population, and the resultant rise in age-related diseases such ...
... Dec. 2 The world,s first concept demonstration ... a petrochemically produced ingredient in the manufacture of synthetic rubber ... week. One tire will be on display at a lounge ... throughout December 21, while the other tire will make appearances ...
... LELYSTAD, The Netherlands, December 2 Pepscan ... for the generation of immune therapeutics today announced that it,has ... , Dr. Mol will be responsible ... strategic direction of the company. He brings to,Pepscan more than ...
Cached Biology Technology:Reportlinker Adds Neurostimulation - A Global Market Perspective 2Reportlinker Adds Neurostimulation - A Global Market Perspective 3Reportlinker Adds Neurostimulation - A Global Market Perspective 4Reportlinker Adds Neurostimulation - A Global Market Perspective 5Reportlinker Adds Neurostimulation - A Global Market Perspective 6The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Dutch Biotech Company Pepscan Appoints New CEO 2
(Date:7/9/2015)... , July 07, 2015 ... announced the addition of the "Biometrics for ... Forecasts 2015-2020" report to their offering. ... major contributor to this growth and the forecast ... billion in revenue for companies involved in delivering ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... BETHESDA, Md. (July 24, 2012)Childhood obesity has nearly tripled in ... those 2-19 years of age were classified as obese. If ... likely that today,s children could be the first generation in ... due to the epidemic of childhood obesity which leads to ...
... antimicrobial peptides, are made in immune system cells and epithelial ... gut). One of these peptides, human neutrophil peptide 1, ... works remains unclear. HIV entry into mature ... attachment of the virus to specific targets on T-helper cells, ...
... that convert electricity into methane gas could become an ... Stanford and Pennsylvania State universities. Researchers at both ... have the remarkable ability to turn electrical energy into ... The scientists, goal is to create large microbial factories ...
Cached Biology News:To understand childhood obesity, researchers look to inactive, fat rats 2To understand childhood obesity, researchers look to inactive, fat rats 3Under the right conditions, peptide blocks HIV infection at multiple points along the way 2Stanford-Penn State scientists use microbes to make 'clean' methane 2Stanford-Penn State scientists use microbes to make 'clean' methane 3Stanford-Penn State scientists use microbes to make 'clean' methane 4
... numbers of samples may be carried out using ... minimum operator attention. System control and data ... CE 4900. The elegant, powerful and very ... and Windows 98 and 2000., The supplied automatic ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
... This CLS number is a new ... Cornings product number. If showing no ... old Sigma-Aldrich number (E6152) or contact ... Dim: H diam. 11.25 ...
A convenience pack containing one each of the most popular sizes of Cat. No. 4980 flask. Designed for the low volume user, a case contains one each of five sizes: 50mL, 125mL, 250mL, 500mL, and 1L....
Biology Products: